CD4+/CD56+ hematodermic neoplasm ("blastic natural killer cell lymphoma"): Neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon

American Journal of Clinical Pathology

Volumn 128, Issue 3, 2007, Pages 445-453

  Pilichowska, Monika E ^a,c   Fleming, Mark D ^b   Pinkus, Jack L ^a   Pinkus, Geraldine S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

BDCA 2; Blastic NK cell lymphoma; CD123; Hematodermic neoplasm; Plasmacytoid dendritic cells

Indexed keywords

ALPHA INTERFERON; CD123 ANTIGEN; CD1C ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CELL MARKER; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYCOPROTEIN P 15095; MICROSOMAL AMINOPEPTIDASE; MYXOVIRUS RESISTANCE PROTEIN; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANDIDEMIA; CASE REPORT; CHROMOSOME ANALYSIS; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MALE; MORTALITY; NATURAL KILLER CELL; PRIORITY JOURNAL; SKIN BIOPSY;

ADOLESCENT; AGED; ANTIGENS, CD4; ANTIGENS, CD56; DENDRITIC CELLS; FEMALE; GTP-BINDING PROTEINS; HUMANS; IMMUNOPHENOTYPING; LECTINS, C-TYPE; LYMPHOMA, NON-HODGKIN; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC;

EID: 34748894440     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/W9Q5AGYDE5LANN39     Document Type: Article

References (37)

1. Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours.
2. Petrella T, Dalac S, Maynadie M, et al. CD4+CD56+ cutaneous neoplasms: a distinct hematological entity? Am J Surg Pathol. 1999;23:137-146.
3. Petrella T, Comeau MR, Maynadie M, et al. Agranular CD4+CD56+ hematodermic neoplasm (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol. 2002;26:852-862.
4. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97:3210-3217.
5. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123:662-675.
6. Hallermann C, Middel P, Griesinger F, et al. CD4+CD56+ blastic tumor of the skin: cytogenetic observations and further evidence of an origin from plasmacytoid dendritic cells. Eur J Dermatol. 2004;14:317-322.
7. Jacob MC, Chaperot L, Mossuz P, et al. CD4+CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica. 2003;88:941-955.
8. Reichard KK, Burks EJ, Foucar MK, et al. CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol. 2005;29:1274-1283.
9. Urosevic M, Curdin C, Kamarashev J, et al. CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. Hum Pathol. 2005;36:1020-1024.
10. Liu YJ. Uncover the mystery of plasmacytoid dendritic cell precursors or type 1 interferon producing cells by serendipity. Hum Immunol. 2002;63:1067-1071.
11. McLellan AD, Kampgen E. Functions of myeloid and lymphoid dendritic cells. Immunol Lett. 2000;72:101-105.
12. Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000;165:6037-6046.
13. Dzionek A, Yoshiaki S, Nagafune J, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J Exp Med. 2001;194:1823-1834.
14. Dzionek A, Inagaki Y, Okawa K, et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol. 2002;63:1133-1148.
15. Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999;5:919-923.
16. H1 polarization. Nat Immunol. 2000;1:305-310.
17. Kadowaki N, Antonenko S, Lau JY, et al. Natural interferon alpha/beta producing cells link innate and adaptive immunity. J Exp Med. 2000;192:219-226.
18. Wu H, Said JW, Ames ED, et al. First reported cases of intravascular large cell lymphoma of the NK cell type. Am J Clin Pathol. 2005;123:603-611.
19. Kutok JL, Pinkus GS, Dorfman DM. Inflammatory pseudotumor of lymph node and spleen: an entity biologically distinct from inflammatory myofibroblastic tumor. Hum Pathol. 2001;32:1382-1387.
20. DiGiuseppe JA, Louie DC, Williams JE, et al. Blastic natural killer cell leukemia/lymphoma: a clinicopathologic study. Am J Surg Pathol. 1997;21:1223-1230.
21. Olweus J, BitMansour A, Warnke R, et al. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci U S A. 1997;94:12551-12556.
22. Galibert L, Maliszewski CR, Vandenabeele S. Plasmacytoid monocytes/T-cells: a dendritic cell lineage? Semin Immunol. 2001;13:283-289.
23. Facchetti F, Vermi W, Mason D, et al. The plasmacytoid monocyte/interferon producing cells. Virchows Arch. 2003;443:703-717.
24. Jahnsen FL, Farkas L, Lundt-Johansen F, et al. Involvement of plasmacytoid dendritic cells in human diseases. Hum Immunol. 2002;63:1201-1205.
25. Pilichowska ME, Pinkus JL, Pinkus GS. Histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease): lesional cells exhibit an immature dendritic cell phenotype and produce interferon [abstract]. Mod Pathol. 2005;18(suppl 1):246A.
26. Grouard G, Rissoan MC, Filgueira L, et al. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med. 1997;185:1101-1111.
27. Facchetti F, Candiago E, Vermi W. Plasmacytoid monocytes express IL3-receptor alpha and differentiate into dendritic cells [letter]. Histopathology. 1999;35:88-89.
28. Khoury JD, Medeiros LJ, Manning JT, et al. CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer. 2002;94:2401-2408.
29. Herling M, Teitell MA, Shen RR, et al. TCL1 expression in plasmacytoid dendritic cells (DC2) and the related CD4+CD56+ blastic tumors of skin. Blood. 2003;101:5007-5009.
30. Petrella T, Meijer CJLM, Dalac S, et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol. 2004;122:307-313.
31. Comeau MR, Van der Vuurst deVries AR, Maliszewski CR, et al. CD123 bright plasmacytoid predendritic cells: progenitors undergoing cell fate conversion? J Immunol. 2002;169:75-83.
32. Pinkus GS, Pinkus JL, Langhoff E, et al. Fascin, a sensitive new marker for Reed-Sternberg cells of Hodgkin's disease: evidence for a dendritic or B cell derivation? Am J Pathol. 1997;150:543-562.
33. Pinkus GS, Lones MA, Matsumura F, et al. Langerhans cell histiocytosis: immunohistochemical expression of fascin, a dendritic cell marker. Am J Clin Pathol. 2002;118:335-343.
34. Jaye DL, Geigerman CM, Herling M, et al. Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. Mod Pathol. 2006;19:1555-1562.
35. Dijkman R, van Doom R, Szuhai K, et al. Gene expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood. 2007;109:1720-1727.
36. Bekkenk MW, Jansen PM, Meijer CJ, et al. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004;15:1097-1108.
37. Orazi A, Chiu R, O'Malley DP, et al. Chronic myelomonocytic leukemia: the role of bone marrow biopsy immunohistology. Mod Pathol. 2006;19:1536-1545.